Treatment for CPAP Intolerant Patients

Inspire Therapy is a Treatment Option for Obstructive Sleep Apnea Patients Who Are Unable To Use CPAP
  • A small device inserted in an outpatient procedure
  • Restores muscle tone to open the airway
  • Patient controlled with the Inspire Sleep Remote
  • Cloud-based adherence monitoring
  • Covered by most U.S. insurance companies

Many of your patients may be eligible for Inspire.

Eligibility considerations:

  • Moderate to severe OSA (AHI 15-100)
  • Unable to get consistent benefit from CPAP
  • Are not significantly overweight
  • Are at least 18 years of age




Inspire SleepSync™ Patient Management Platform

Web-based monitoring of OSA quality measures like therapy adherence.

Stimulation Therapy for Apnea Reduction Clinical Trial Outcomes

The Stimulation Therapy for Apnea Reduction (STAR) clinical trial began in 2010 at 22 leading medical centers across the United States and Europe. One-year STAR Trial outcome measures were published in the January 9, 2014 version of the New England Journal of Medicine. Results showed that sleep apnea patients receiving Inspire therapy experienced significant reductions in sleep apnea events and significant improvements in quality of life measures .

The significant improvements and reductions measured after 1-year were sustained over a 5-year follow-up period. The outcomes include:

  • 79% reduction in AHI events (Figure 1)
  • Significant improvements in daytime functioning as measured by FOSQ score (Figure 2)
  • Significant reductions in daytime sleepiness as measured by the ESS (Figure 3)
  • 90% of bed partners reported soft or no snoring for their partner, as compared to only 17% of bed partners at baseline (Figure 4)


Figure 1: Significant Reduction in Apnea-Hypopnea Events

Figure 2: Significant Improvements in Daytime Functioning

Figure 3: Significant Reductions in Daytime Sleepiness

Figure 4: Significant Reduction in Bed Partner Reported Snoring

What Doctors Are Saying